Patents Assigned to Axsome Malta Ltd.
-
Patent number: 11969404Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: April 3, 2023Date of Patent: April 30, 2024Assignee: AXSOME MALTA LTD.Inventor: Katayoun Zomorodi
-
Patent number: 11872204Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: May 24, 2023Date of Patent: January 16, 2024Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11872203Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: May 24, 2023Date of Patent: January 16, 2024Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11865098Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.Type: GrantFiled: May 12, 2023Date of Patent: January 9, 2024Assignee: Axsome Malta Ltd.Inventors: Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
-
Patent number: 11857528Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: June 22, 2023Date of Patent: January 2, 2024Assignee: Axsome Malta Ltd.Inventor: Katayoun Zomorodi
-
Patent number: 11850226Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: March 31, 2023Date of Patent: December 26, 2023Assignee: Axsome Malta Ltd.Inventor: Katayoun Zomorodi
-
Patent number: 11850228Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: April 3, 2023Date of Patent: December 26, 2023Assignee: Axsome Malta Ltd.Inventor: Katayoun Zomorodi
-
Patent number: 11850227Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: March 31, 2023Date of Patent: December 26, 2023Assignee: Axsome Malta Ltd.Inventor: Katayoun Zomorodi
-
Patent number: 11839599Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: March 31, 2023Date of Patent: December 12, 2023Assignee: Axsome Malta Ltd.Inventor: Katayoun Zomorodi
-
Patent number: 11839598Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: March 31, 2023Date of Patent: December 12, 2023Assignee: Axsome Malta Ltd.Inventor: Katayoun Zomorodi
-
Patent number: 11793776Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: March 1, 2023Date of Patent: October 24, 2023Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11780805Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.Type: GrantFiled: September 9, 2021Date of Patent: October 10, 2023Assignee: Axsome Malta Ltd.Inventors: Fionn Hurley, Lawrence Patrick Carter
-
Patent number: 11779554Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: March 1, 2023Date of Patent: October 10, 2023Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11771667Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: March 1, 2023Date of Patent: October 3, 2023Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11771666Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: December 30, 2022Date of Patent: October 3, 2023Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11713292Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.Type: GrantFiled: July 23, 2021Date of Patent: August 1, 2023Assignees: Axsome Malta Ltd, SK Biopharmaceuticals Co., Ltd.Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts
-
Patent number: 11648232Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.Type: GrantFiled: March 25, 2021Date of Patent: May 16, 2023Assignee: Axsome Malta Ltd.Inventors: Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
-
Patent number: 11560354Abstract: The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.Type: GrantFiled: November 6, 2020Date of Patent: January 24, 2023Assignees: Axsome Malta Ltd., SK Biopharmaceuticals Co., Ltd.Inventor: Fionn Hurley
-
Patent number: 11497725Abstract: The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.Type: GrantFiled: September 22, 2020Date of Patent: November 15, 2022Assignees: Axsome Malta Ltd., SK Biopharmaceuticals Co., Ltd.Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts
-
Patent number: 11439597Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.Type: GrantFiled: January 21, 2021Date of Patent: September 13, 2022Assignee: Axsome Malta Ltd.Inventors: Clark Patrick Allphin, Edwin Gerard Walsh